Sygnis AG Reports Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Year 2018
For the year 2018, the company expects revenues to be in the range of EUR 11 million to EUR 12 million without considering the impact of TGR Biosciences. This current revenue forecast is based on continued strong organic growth of the product sales in line with the previous year. The management board continues to expect a strong result for 2018 with a positive EBITDA result for the year as well as the group becoming overall cash generative during the course of 2018.